Category: PMCPA Case of the Week

Cases selected for the AskAnzal weekly PMCPA insight newsletter

8 Mar 2026

AUTH/3724/1/23: Complainant v GSK (Shingrix) β€” TV shingles awareness advert and website (No breach)

A UK physician alleged a shingles TV ad and linked disease-awareness site indirectly promoted GSK’s Shingrix. PMCPA Panel…

8 Mar 2026

GSK: Responsive disease-awareness website breached Clause 8.3 due to uncertified desktop vs mobile final forms (AUTH/3819/9/23)

PMCPA found GSK’s Tackle Meningitis site showed substantive desktop vs mobile differences on two pages. Each final form…

8 Mar 2026

GSK breach for patient organisation articles: funding acknowledgement not clear from the outset (AUTH/3895/5/24)

Four patient-facing articles funded by a GSK grant disclosed the funding only at the bottom of each page.…

8 Mar 2026

AUTH/2141/7/08: Novo Nordisk v Sanofi-Aventis – Promotion of Lantus (claims on 24-hour efficacy and hypoglycaemia risk)

Complaint about Lantus promotional leavepieces and a mailer. Issues included β€œ24-hour efficacy” wording and a hypoglycaemia comparison based…

8 Mar 2026

Boehringer Ingelheim v Bayer Schering Pharma: pre-licence promotion of Xarelto via congress stand and JBJS insert

Bayer Schering was found to have promoted Xarelto (rivaroxaban) before UK authorisation via a UK congress exhibition panel…

8 Mar 2026

Lilly v Novo Nordisk: Victoza launch materials, media briefings and patient support (AUTH/2273/10/09)

Novo Nordisk’s Victoza launch activity led to multiple Code breaches, mainly around misleading claims, lack of balance/safety info,…

8 Mar 2026

Astellas: misleading PMCPA submissions about advisory board delegate selection led to public reprimands, audits and ABPI suspension (AUTH/2780/7/15)

Anonymous employee alleged Astellas misled PMCPA about Milan advisory board delegate selection. Panel/Appeal Board found false/incomplete information and…

8 Mar 2026

AUTH/2405/5/11: Meda v ALK-AbellΓ³ (Jext leavepiece) – No breach

Intercompany complaint about Jext leavepiece diagrams and the claim β€œdesigned to be easy to use”. Panel found the…

8 Mar 2026

AUTH/3068/9/18: Director v Sanofi β€” Clinical trial disclosure (outwith scope; no breach)

PMCPA case AUTH/3068/9/18 (Director v Sanofi) concerned clinical trial disclosure but was ruled outwith the scope of the…

8 Mar 2026

Anonymous v Pierre Fabre: representative emails about β€˜oral chemotherapy clinics’ ruled non-promotional (no breach)

Anonymous complaint alleged unsolicited promotional emails to NHS staff about setting up β€˜oral chemotherapy’ clinics without consent or…

⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week β€” free.

Subscribe Free
🎓 AQP Training